Clinical risk factors related to treatment failure in Mycobacterium abscessus lung disease

被引:0
|
作者
Keiji Fujiwara
Koji Furuuchi
Akio Aono
Fumiko Uesugi
Tatsuya Shirai
Keitaro Nakamoto
Takafumi Shimada
Fumi Mochizuki
Yoshiaki Tanaka
Hiroaki Iijima
Takashi Yoshiyama
Yuji Shiraishi
Atsuyuki Kurashima
Ken Ohta
Satoshi Mitarai
Kozo Morimoto
机构
[1] Fukujuji Hospital,Respiratory Disease Center
[2] Japan Anti-Tuberculosis Association,Department of Mycobacterium Reference and Research
[3] The Research Institute of Tuberculosis,Department of Respiratory Medicine
[4] Japan Anti-Tuberculosis Association,Department of Respiratory Medicine
[5] Kyorin University School of Medicine,Division of Clinical Research
[6] Tsukuba Medical Center,undefined
[7] Fukujuji Hospital,undefined
[8] Japan Anti-Tuberculosis Association,undefined
关键词
Treatment outcomes; Lung disease; Cavity;
D O I
暂无
中图分类号
学科分类号
摘要
The clinical importance of Mycobacterium abscessus subsp. abscessus (M. abscessus) lung disease has been increasing, but few studies have assessed the clinical characteristics associated with the treatment outcome. We retrospectively analyzed 75 consecutive patients with M. abscessus lung disease diagnosed at a tertiary hospital from January 2004 to April 2018. Among 52 patients with sufficient clinical data, 19 patients (42.2%) achieved treatment success. Compared with 26 (57.8%) patients in the treatment failure group, body mass index (BMI) (19.8 vs 17.5 kg/m2, P = 0.022), previous nontuberculous mycobacterial (NTM) lung disease (26.3% vs 61.5%, P = 0.034), the presence of cavitary lesions (31.6% vs 69.2%, P = 0.017), and the bronchiectasis score (3.0 vs 5.0, P = 0.003) were significantly different in the treatment success group. Multivariate analysis showed that age (adjusted hazard ratio (aHR), 0.94; 95% confidence interval (CI), 0.90 to 0.99; P = 0.010), the presence of cavitary lesions (aHR, 0.34; 95% CI, 0.12 to 0.94; P = 0.039), and previous NTM lung disease (aHR, 0.28; 95% CI, 0.09 to 0.86; P = 0.026) were negatively associated with treatment success. This is the first study to show that previous NTM lung disease might be a clinically important factor related to unfavorable treatment outcomes in M. abscessus lung disease patients. To increase our understanding the characteristics of M. abscessus lung disease, this factor should be independently analyzed in future research.
引用
收藏
页码:247 / 254
页数:7
相关论文
共 50 条
  • [41] Durlobactam to boost the clinical utility of standard of care β-lactams against Mycobacterium abscessus lung disease
    Negatu, Dereje A.
    Aragaw, Wassihun Wedajo
    Gebresilase, Tewodros T.
    Paruchuri, Sindhuja
    Kaya, Firat
    Shin, Sung Jae
    Sander, Peter
    Dartois, Veronique
    Dick, Thomas
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2025, 69 (01)
  • [42] Risk Factors for Recurrence after Successful Treatment of Mycobacterium avium Complex Lung Disease
    Lee, Bo Young
    Kim, Sunyoung
    Hong, YoonKi
    Lee, Sang-Do
    Kim, Woo Sung
    Kim, Dong Soon
    Shim, Tae Sun
    Jo, Kyung-Wook
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (06) : 2972 - 2977
  • [43] Predictive risk factors of treatment-refractory Mycobacterium avium complex lung disease
    Saito, Takahiko
    Aono, Yuya
    Kono, Masato
    Sugiura, Takuma
    Higasa, Misato
    Katsumata, Mineo
    Miwa, Hideki
    Miki, Yoshihiro
    Hashimoto, Dai
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [44] Comparison Of Clinical Course And Treatment Outcome Of Mycobacterium Abscessus Complex Lung Infection Depending On Subspecies
    Kono, S.
    Matsui, H.
    Kawashima, M.
    Nagai, H.
    Watanabe, K.
    Kato, T.
    Watanabe, N.
    Oshima, N.
    Ota, K.
    Mitarai, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [45] MYCOBACTERIUM ABSCESSUS LUNG DISEASE IN A PATIENT WITH PREVIOUS PULMONARY TUBERCULOSIS
    Duan Hongfei
    Huang Xuerui
    Wang Jing
    Chu Naihui
    SOUTHEAST ASIAN JOURNAL OF TROPICAL MEDICINE AND PUBLIC HEALTH, 2012, 43 (04) : 959 - 963
  • [46] An Intensified Regimen Containing Linezolid Could Improve Treatment Response in Mycobacterium abscessus Lung Disease
    Li, Hua
    Tong, Li
    Wang, Jun
    Liang, Qingtao
    Zhang, Yun
    Chu, Naihui
    Chen, Xiaoyou
    Duan, Hongfei
    BIOMED RESEARCH INTERNATIONAL, 2019, 2019
  • [47] Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease
    Negatu, Dereje A.
    Zimmerman, Matthew D.
    Dartois, Veronique
    Dick, Thomas
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (09)
  • [48] Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense (vol 64, pg 301, 2016)
    Park, J.
    Cho, J.
    Lee, C. H.
    CLINICAL INFECTIOUS DISEASES, 2017, 64 (10) : 1469 - 1469
  • [49] Risk factors for hemoptysis in Mycobacterium avium complex lung disease
    Minomo, Shojiro
    Kobayashi, Takehiko
    Katayama, Kanako
    Ryuge, Misaki
    Kagawa, Tomoko
    Tsuyuguchi, Kazunari
    Matsui, Hideo
    Suzuki, Katsuhiro
    RESPIRATORY INVESTIGATION, 2021, 59 (02) : 218 - 222
  • [50] Spontaneous sputum conversion and reversion in Mycobacterium abscessus complex lung disease
    Jo, Kyung-Wook
    Park, Yea Eun
    Chong, Yong Pil
    Shim, Tae Sun
    PLOS ONE, 2020, 15 (04):